2024
Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer.
Bei, Y., Brame, Luca, Kirchner, M., Fritsche-Guenther, R., Kunz, S., Bhattacharya, A., Rusu, M.C., Gürgen, D., Dubois, F.P.B., Köppke, J.K.C., Proba, J., Wittstruck, N., Sidorova, O.A., Chamorro González, R., Dorado Garcia, H., Brückner, L., Xu, R., Giurgiu, M., Rodriguez-Fos, E., Yu, Q., Spanjaard, B., Koche, R.P., Schmitt, C.A., Schulte, J.H., Eggert, A., Haase, K., Kirwan, J., Hagemann, A.I., Mertins, P., Dörr, J.R. and Henssen, A.G.
Cancer Discovery 14
(3): 492-507.
1 March 2024
2021
Germline mutations including the rare pathogenic variant c.3206delC in the ATM gene cause ataxia teleangiectasia-associated primary central nervous system lymphoma.
Dörr, J.R., Thorwarth, A., Mizia-Malarz, A., Radke, J., Tietze, A., Hernáiz-Driever, P., Horn, D., Gratopp, A., Eggert, A. and Deubzer, H.E.
Children 8
(6): 469.
June 2021
2020
H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients.
Schleich, K., Kase, J., Dörr, J.R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E.M., Fan, D.N.Y., Lohneis, P., Milanovic, M., Lau, A., Lenze, D., Hummel, M., Chapuy, B., Leser, U., Reimann, M., Lee, S. and Schmitt, C.A.
Nature Communications 11
(1): 3651.
20 July 2020
2018
Senescence-associated reprogramming promotes cancer stemness.
Milanovic, M., Fan, D.N.Y., Belenki, D., Däbritz, J.H.M., Zhao, Z., Yu, Y., Dörr, J.R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I.A., Mendoza-Parra, M.A., Kanashova, T., Metzner, M., Pardon, K., Reimann, M., Trumpp, A., Dörken, B., Zuber, J., Gronemeyer, H., Hummel, M., Dittmar, G., Lee, S. and Schmitt, C.A.
Nature 553
(7686): 96-100.
4 January 2018
2016
CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M., Yu, Y., Milanovic, M., Schönlein, M., Rosenfeldt, M.T., Dörr, J.R., Kaufmann, A.M., Dörken, B. and Schmitt, C.A.
Molecular Cancer Therapeutics 15
(5): 1074-1081.
May 2016
2013
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J.H.M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., Kratzat, S., Purfürst, B., Walenta, S., Mueller-Klieser, W., Gräler, M., Hummel, M., Keller, U., Buck, A.K., Dörken, B., Willmitzer, L., Reimann, M., Kempa, S., Lee, S. and Schmitt, C.A.
Nature 501
(7467): 421-425.
19 September 2013
2011
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Jing, H., Kase, J., Dörr, J.R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., Hummel, M., Doerken, B., Lenz, G., Scheidereit, C., Schmitt, C.A. and Lee, S.
Genes & Development 25
(20): 2137-2146.
15 October 2011
2010
Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J.R., Tabor, V., Aichele, P., Stein, H., Doerken, B., Jenuwein, T. and Schmitt, C.A.
Cancer Cell 17
(3): 262-272.
16 March 2010
This list was generated on Wed Nov 13 16:56:19 2024 UTC.